Intellectual Property
PIKAMAB’s patent portfolio includes licensed and owned patents and patent applications that relate to stratification of patients for the purposes of selection and treatment, MAb/Fc engineering, and development of MAbs and vaccines. PIKAMAB’s antibody engineering platformoffers strategic advantages in Fc engineering. The Company is developing proprietary MAbsto improve the clinical efficacy of the currently marketed ADCC-MAbs.
Secondly, because of its proprietary position, PIKAMAB is uniquely positioned to advance the field of MAb theragnostics. In the ADCC-treatable diseases and disorders, our proprietary platform allows us to stratify patients into three groups in each dimension (FcGR-3A: VV, VF, FF158; and FcGR-2A: HH, HR, RR131). Such two-dimensional stratification is both critical and necessary to develop the theragnostic assays.
In stratified medicine, we have developed proprietary methods for:
- selecting a patient for treatment with an antibody;
- treating a patient with an antibody;
- determining the degree of responsiveness;
- selecting a specific variant antibody therapy from a set of two or more variant antibody therapies for use in treatment;
- modulating responsiveness of a patient to an antibody therapy; and
- enhancing the ADCC activity of an antibody for use in treatment of a patient having an ADCC-treatable disease.
In addition, our proprietary methods include the use of:
- FcGR genes and proteins and their polymorphisms to determine the severity of autoimmune diseases such as lupus, lupus nephritis, rheumatoid arthritis, systemic vasculitis, mixed connective tissue disease, Sjögren’s syndrome, and Wegener’s granulomatosis, and
- FcGR-2B promoter polymorphisms to predict treatment outcome, prescribe effective therapeutic drugs, and predict likelihood of patients developing systemic lupus erythematosus.
In the autoimmune diseases space, theragnostic assays will developed by incorporating the use of additional FcGR polymorphisms (FcGR-2B; FcGR-3B) to our 3×3 Matrix
Highlights
PIKAMAB’s 3×3 Matrix™ approach offers significant value in:
- Better treatment with marketed MAbs through the development of theragnostic products, ADCC Therasight and Lupus Therasight;
- Co-development of MAb theragnostic products for new or follow-on therapeutic MAbs;
- More efficient development of MAb therapies through patient stratification in clinical trials so that guided drug development process can lead to reduced attrition;
- More effective discovery and development of novel MAbs and vaccines.
Click to enlarge